2448172-22-1
Chemical Structure
Icovamenib
Synonym(s): BMF-219; Menin-MLL inhibitor 21
- CAS No.: 2448172-22-1
- Formula:C31H34N8O3
- Molecular Weight:566.65
IUPAC Name: (R)-4-((3-acrylamidopiperidin-1-yl)methyl)-N-(4-(4-morpholino-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)picolinamide
InChIKey: CPRLHPSXWZTPMC-XMMPIXPASA-N
SMILES: O=C(C1=CC(CN2C[C@@H](CCC2)NC(C=C)=O)=CC=N1)NC3=CC=C(C=C3)C4=CC5=C(N6CCOCC6)N=CN=C5N4
Biological Activity: Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Icovamenib | 98.96% | Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Thomas Butler, et al. Irreversible inhibitors of menin-mll interaction.WO2020142557 A1.
- [2]. Jeffrey Lancet MD, et al. Dovalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study. Blood. Volume 142, Supplement 1, 2 November 2023, Page 2916.
- [3]. Mo J, et al. Design, synthesis, and evaluation of Menin-targeting compounds for the treatment of acute Myelocytic leukemia (AML). Eur J Med Chem. 2025 Jun 12;296:117847. [Content Brief]
- [4]. Mini Balakrishnan, et al., Combination of Icovamenib and GLP-1-based Therapeutic Agents Improves Beta Cell Function and Insulin Secretion. Metabolism - Clinical and Experimental, Volume 168, 156226.
- [5]. Carraway, H. E., et al., (2025). Complete remission of NUP98 fusion-positive acute myeloid leukemia with the covalent menin inhibitor BMF-219, icovamenib. Haematologica, 110(4), 1041–1046. [Content Brief]
Keywords
